Serum Soluble CD14 Is a Potential Prognostic Indicator of Recurrence of Human Breast Invasive Ductal Carcinoma with Her2-Enriched Subtype
Figure 2
Determination of serum sCD14 concentrations in patients of LN-ER/PR+Her2- and LN+ER/PR- Her2+ phenotype breast cancer by ELISA.
A significantly higher level of serum sCD14 was observed in patients with LN-ER/PR+Her2- status (n=93) than in that with LN+ER/PR-Her2+ status (n=90) (p<0.0001).